^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Perjeta (pertuzumab) (HER2 dimerization inhibitor) + Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Published date:
11/05/2021
Excerpt:
Both T-DM1/P and THP arms ‘graduate’ in all subtypes: predicted pCR rates are 63%, 72% and 33% for T-DM1/P (n = 52), THP (n = 45) and TH (n = 31) respectively. Amongst all HER2+ patients in the TDM-1/P and TH arms, T-DM1/P had a higher estimated pCR rate (55%; 95% PI 41–69%) than TH (25%; 95% PI 11–38%), corresponding to a 99.9% probability that T-DM1/P was superior to TH...In summary, both T-DM1/P and THP significantly increased estimated pCR rates over TH in HER2+ patients, within both HR+ and HR– groups.
DOI:
https://doi.org/10.1038/s41467-021-26019-y
Trial ID:
